Pharmacokinetic considerations for therapies used to treat interstitial cystitis

Barbara Gardella, Daniele Porru, Massimo Allegri, Stefano Bogliolo, Anna Daniela Iacobone, Cristina Minella, Rossella Elena Nappi, Simone Ferrero, Arsenio Spinillo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Interstitial cystitis (IC) or bladder pain syndrome (BPS) is defined as supra-pubic pain related to bladder filling. IC is characterized by a particular symptom complex with no identifiable causes; as with bladder hypersensitivity it is usually associated with urinary frequency and urgency with bladder pain. No current treatments have a significant impact on symptoms over time. Areas covered: This systematic review examines the pharmacokinetic aspects and adverse event of present IC therapy to highlight appropriate treatment to improve the symptoms of IC. This article reviews material obtained via Medline, PubMed, and EMBASE literature searches up to October 2013. Expert opinion: The correct approach to IC should consider a multidisciplinary team of specialists and a multimodal treatment package that include psychotherapy, behavior change, physical activation, and analgesic treatment. Unfortunately, a single therapeutic target for IC is not yet known. With regard to pathophysiology and therapy, there is more to discover. The first insult damages the bladder urothelium, hence vehicles that lead the drug to penetrate the wall of the bladder might be a novel strategic approach.

Original languageEnglish
Pages (from-to)673-684
Number of pages12
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume10
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Interstitial Cystitis
Pharmacokinetics
Urinary Bladder
Analgesics
Chemical activation
Pain
Therapeutics
Pharmaceutical Preparations
Urothelium
Combined Modality Therapy
Expert Testimony
PubMed
Psychotherapy
Hypersensitivity

Keywords

  • Biofilms
  • Bladder pain syndrome
  • Interstitial cystitis
  • Intravesical liposomes

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Medicine(all)

Cite this

@article{549beac538464c928ce03ba0bca3a088,
title = "Pharmacokinetic considerations for therapies used to treat interstitial cystitis",
abstract = "Introduction: Interstitial cystitis (IC) or bladder pain syndrome (BPS) is defined as supra-pubic pain related to bladder filling. IC is characterized by a particular symptom complex with no identifiable causes; as with bladder hypersensitivity it is usually associated with urinary frequency and urgency with bladder pain. No current treatments have a significant impact on symptoms over time. Areas covered: This systematic review examines the pharmacokinetic aspects and adverse event of present IC therapy to highlight appropriate treatment to improve the symptoms of IC. This article reviews material obtained via Medline, PubMed, and EMBASE literature searches up to October 2013. Expert opinion: The correct approach to IC should consider a multidisciplinary team of specialists and a multimodal treatment package that include psychotherapy, behavior change, physical activation, and analgesic treatment. Unfortunately, a single therapeutic target for IC is not yet known. With regard to pathophysiology and therapy, there is more to discover. The first insult damages the bladder urothelium, hence vehicles that lead the drug to penetrate the wall of the bladder might be a novel strategic approach.",
keywords = "Biofilms, Bladder pain syndrome, Interstitial cystitis, Intravesical liposomes",
author = "Barbara Gardella and Daniele Porru and Massimo Allegri and Stefano Bogliolo and Iacobone, {Anna Daniela} and Cristina Minella and Nappi, {Rossella Elena} and Simone Ferrero and Arsenio Spinillo",
year = "2014",
doi = "10.1517/17425255.2014.896338",
language = "English",
volume = "10",
pages = "673--684",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetic considerations for therapies used to treat interstitial cystitis

AU - Gardella, Barbara

AU - Porru, Daniele

AU - Allegri, Massimo

AU - Bogliolo, Stefano

AU - Iacobone, Anna Daniela

AU - Minella, Cristina

AU - Nappi, Rossella Elena

AU - Ferrero, Simone

AU - Spinillo, Arsenio

PY - 2014

Y1 - 2014

N2 - Introduction: Interstitial cystitis (IC) or bladder pain syndrome (BPS) is defined as supra-pubic pain related to bladder filling. IC is characterized by a particular symptom complex with no identifiable causes; as with bladder hypersensitivity it is usually associated with urinary frequency and urgency with bladder pain. No current treatments have a significant impact on symptoms over time. Areas covered: This systematic review examines the pharmacokinetic aspects and adverse event of present IC therapy to highlight appropriate treatment to improve the symptoms of IC. This article reviews material obtained via Medline, PubMed, and EMBASE literature searches up to October 2013. Expert opinion: The correct approach to IC should consider a multidisciplinary team of specialists and a multimodal treatment package that include psychotherapy, behavior change, physical activation, and analgesic treatment. Unfortunately, a single therapeutic target for IC is not yet known. With regard to pathophysiology and therapy, there is more to discover. The first insult damages the bladder urothelium, hence vehicles that lead the drug to penetrate the wall of the bladder might be a novel strategic approach.

AB - Introduction: Interstitial cystitis (IC) or bladder pain syndrome (BPS) is defined as supra-pubic pain related to bladder filling. IC is characterized by a particular symptom complex with no identifiable causes; as with bladder hypersensitivity it is usually associated with urinary frequency and urgency with bladder pain. No current treatments have a significant impact on symptoms over time. Areas covered: This systematic review examines the pharmacokinetic aspects and adverse event of present IC therapy to highlight appropriate treatment to improve the symptoms of IC. This article reviews material obtained via Medline, PubMed, and EMBASE literature searches up to October 2013. Expert opinion: The correct approach to IC should consider a multidisciplinary team of specialists and a multimodal treatment package that include psychotherapy, behavior change, physical activation, and analgesic treatment. Unfortunately, a single therapeutic target for IC is not yet known. With regard to pathophysiology and therapy, there is more to discover. The first insult damages the bladder urothelium, hence vehicles that lead the drug to penetrate the wall of the bladder might be a novel strategic approach.

KW - Biofilms

KW - Bladder pain syndrome

KW - Interstitial cystitis

KW - Intravesical liposomes

UR - http://www.scopus.com/inward/record.url?scp=84898448328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898448328&partnerID=8YFLogxK

U2 - 10.1517/17425255.2014.896338

DO - 10.1517/17425255.2014.896338

M3 - Article

VL - 10

SP - 673

EP - 684

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 5

ER -